Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ARS Pharmaceuticals Inc SPRY

Healthcare Biotechnology
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and... see more

Recent & Breaking News (NDAQ:SPRY)

SBTX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 4, 2022 in the Class Action Filed on Behalf of Silverback Therapeutics, Inc. Limited Shareholders

Newsfile January 2, 2022

SILVERBACK DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Silverback Therapeutics, Inc. and Encourages Investors to Contact the Firm

Business Wire January 2, 2022

Silverback Shareholder Notice

Newsfile January 2, 2022

SBTX FINAL DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Silverback Therapeutics, Inc. Investors to Secure Counsel Before Important January 4 Deadline in Securities Class Action - SBTX

PR Newswire January 1, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Silverback Therapeutics, Inc., of Class Action Lawsuit and Upcoming Deadline - SBTX

Newsfile December 31, 2021

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Silverback Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

PR Newswire December 31, 2021

SBTX FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Silverback Therapeutics, Inc. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - SBTX

Newsfile December 31, 2021

SBTX TUESDAY DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Silverback Therapeutics, Inc. Investors to Secure Counsel Before Important January 4 Deadline in Securities Class Action - SBTX

Newsfile December 30, 2021

FINAL NOTICE: Silverback Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SBTX

Newsfile December 29, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Silverback Therapeutics, Inc., of Class Action Lawsuit and Upcoming Deadline - SBTX

PR Newswire December 29, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Silverback Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2022 - SBTX

PR Newswire December 27, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Silverback Therapeutics, Inc., of Class Action Lawsuit and Upcoming Deadline - SBTX

Newsfile December 24, 2021

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Silverback Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important January 4 Deadline in Securities Class Action - SBTX

PR Newswire December 23, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Silverback Therapeutics, Inc., of Class Action Lawsuit and Upcoming Deadline - SBTX

PR Newswire December 21, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Silverback Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2022 - SBTX

PR Newswire December 21, 2021

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Silverback Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important January 4 Deadline in Securities Class Action - SBTX

Business Wire December 17, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Silverback Therapeutics, Inc., of Class Action Lawsuit and Upcoming Deadline - SBTX

Newsfile December 16, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Silverback Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2022 - SBTX

PR Newswire December 15, 2021

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Silverback Therapeutics, Inc. Investors With Losses Over $100K to Secure Counsel Before Important January 4 Deadline in Securities Class Action - SBTX

PR Newswire December 14, 2021

Silverback Shareholder Alert

Newsfile December 14, 2021